Dr. Furst has served as a paid consultant with investment analysts as a member of the Advisory Boards for Actelion and Gilead ($3,000 each).
Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double-blind, randomized controlled trials
Article first published online: 30 JUL 2009
Copyright © 2009 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 60, Issue 8, pages 2490–2498, August 2009
How to Cite
Amjadi, S., Maranian, P., Furst, D. E., Clements, P. J., Wong, W. K., Postlethwaite, A. E., Khanna, P. P. and Khanna, D. (2009), Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis & Rheumatism, 60: 2490–2498. doi: 10.1002/art.24681
- Issue published online: 30 JUL 2009
- Article first published online: 30 JUL 2009
- Manuscript Accepted: 15 APR 2009
- Manuscript Received: 3 JUL 2008
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)/National Institute of Allergy and Infectious Diseases). Grant Number: N01-AR-902242
- Department of Veterans Affairs
- Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training grant from NIAMS. Grant Number: 1 T32-AR-053463
- NIAMS. Grant Number: K23-AR-053858-01A1
- New Investigator award from the Scleroderma Foundation
- 1Classification prognosis. In: ClementsPJ, FurstDE, editors. Systemic sclerosis. Baltimore: Williams & Wilkins; 1996. p. 51–64., .
- 8Cutaneous involvement in systemic sclerosis. In: ClementsP, FurstDE, editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 129–50., , .
- 13CAT-192 Study Group and the Scleroderma Clinical Trials Consortium. Recombinant human anti– transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56: 323–33., , , , , , et al, on behalf of the
- 15Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009; 60: 1102–11., , , , , , et al, for the
- 16A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis. I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 2008; 58: 1810–22., , , , , , et al.
- 21U.S. phase III trial of relaxin in diffuse scleroderma [abstract]. J Rheumatol 2001; 28 Suppl 63: 55., , , , , , et al.